Skip to main content

Table 2 Summary of patient characteristics and demographics and change in BMD following discontinuation of etidronate or alendronate.

From: The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis

  Didronel PMO (n = 19) Fosamax (n = 16)
Age at Discontinuation (mean [SD]) 64.3 [14.41] 69.4 [9.23]
Years on Treatment (mean [SD]) 6.8 [2.21] 5.6 [1.03] *
Age at Menarche (mean [SD]) 13.0 [1.664] 12.8 [2.49]
Number of years since menopause (mean [SD]) 24.7 [9.18] 27.36 [9.04]
Milk Intake ≥ 1/2 pint/day (%) 15.8 6.25
Walking < 30 minutes/day 36.48 25
(%) > 1 hour/day 5.26 12.5
Previous fragility fracture(s) (%) 26.32 37.5
BMI (Kg/m2) (mean [SD]) 25.47 [6.27] 26.48 [4.67]
Current and Ex-Smokers (%) 36.84 18.75
Alcohol Intake ≤ 14 units/week (%) 52.63 37.5
Positive Family History of Osteoporosis (%) 42.12 25
Lumbar Spine BMD at discontinuation (g/cm2) (mean [SD]) 0.856 [0.118] 0.761 [0.106]
Lumbar Spine BMD after discontinuation (g/cm2) (mean [SD]) 0.855 [0.107] 0.769 [0.106]
Total Hip BMD at discontinuation (g/cm2) (mean [SD]) 0.794 [0.133] 0.739 [0.105]
Total Hip BMD after discontinuation (g/cm2) (mean [SD]) 0.792 [0.129] 0.736 [0.099]
  1. * p = 0.029